Wave Life Sciences to Present at Jefferies London Healthcare Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) has announced its participation in the Jefferies London Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will engage in an analyst-led fireside chat on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.

The presentation will be accessible through a live webcast in the 'Investor Events' section of Wave Life Sciences' website. A replay will be available for a time after the event.

11/15/2024 - 08:30 AM

CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.

A live webcast of this presentation can be accessed by visiting “Investor Events” on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM^®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.

Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com

FAQ

When is Wave Life Sciences (WVE) presenting at the Jefferies London Healthcare Conference 2024?

Wave Life Sciences is scheduled to present on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.

How can investors watch Wave Life Sciences' (WVE) presentation at the Jefferies Conference?

Investors can watch the presentation through a live webcast available in the 'Investor Events' section of Wave Life Sciences' website at ir.wavelifesciences.com/events-publications/events.